Abstract
Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly being used to treat indolent and aggressive B-cell non-Hodgkin's lymphoma. Rituximab is considered a relatively safe drug, but recently, severe and fatal adverse effects related to this drug have been reported. In this regard, we report an 80-year-old patient with follicular grade 3 non-Hodgkin's lymphoma who developed a fatal interstitial pneumonitis related to treatment with a rituximab/CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen. The pneumonitis was diagnosed on a routine midtreatment positron emission tomography/computed tomography scan when the patient was almost asymptomatic. Pulmonary deterioration occurred as the treatment with rituximab/CHOP was continued. In this article, we also review the literature on rituximab-associated pneumonitis, and we discuss the differential diagnosis with cyclophosphamide-induced lung injury.
References
Dec 1, 1996·American Journal of Respiratory and Critical Care Medicine·S W MalikU Specks
Oct 6, 2001·Leukemia·N SelenkoJ Stöckl
Feb 15, 2002·British Journal of Haematology·L E van der KolkM H van Oers
Mar 26, 2002·Leukemia & Lymphoma·S KanelliT E Witzig
Sep 7, 2002·American Journal of Hematology·Yair Herishanu
Oct 24, 2002·Blood·John C ByrdRichard A Larson
Nov 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LowndesA Lister
Jun 27, 2003·The New England Journal of Medicine·Catherine BurtonRiaz Jan-Mohamed
Jun 27, 2003·The New England Journal of Medicine·Eric VoogPhilippe Solal-Céligny
Aug 22, 2003·Blood·Timm H WesthoffEckhard Thiel
Jan 30, 2004·Annual Review of Medicine·William RastetterChristine A White
Aug 13, 2004·American Journal of Hematology·R SwordsP T Murphy
Oct 30, 2004·Leukemia & Lymphoma·Doru T AlexandrescuPeter H Wiernik
Citations
Apr 28, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Marie-Camille ChaumaisGeorges Deschênes
Nov 15, 2011·Targeted Oncology·Nicholas A Barber, Apar Kishor Ganti
Apr 15, 2008·International Journal of Hematology·Daisuke EnnishiKiyohiko Hatake
Dec 18, 2009·Anti-cancer Drugs·Maajid Mumtaz PeerzadaHamed A Daw
Jul 16, 2010·Clinical Nuclear Medicine·Bong-Il SongKyung-Min Shin
Dec 14, 2011·Rheumatology·Andreas V HadjinicolaouAndrew J K Ostör
May 21, 2009·Leukemia & Lymphoma·Dimitrios KalkanisIzidore S Lossos
Sep 18, 2008·Leukemia & Lymphoma·Xin LiuJunning Cao
Apr 29, 2009·Leukemia & Lymphoma·Ron RamPia Raanani
Oct 31, 2014·Leukemia & Lymphoma·Giselle SalmasiJ Kuruvilla
Dec 30, 2009·Leukemia & Lymphoma·C VulstekeP Schöffski
Aug 10, 2010·Clinics in Chest Medicine·Keith C MeyerRobert Baughman
Apr 22, 2008·Joint, Bone, Spine : Revue Du Rhumatisme·Huguette Lioté
Aug 15, 2009·Pediatric Pulmonology·Martin BitzanLucy Carpineta
Mar 20, 2013·Journal of Clinical Pharmacy and Therapeutics·Yongkang WuYu Wu
May 24, 2012·Internal Medicine Journal·T Shen, S Braude
Jul 11, 2012·Case Reports in Medicine·Ahmet B ErginHamed A Daw
Mar 24, 2015·Clinical Case Reports·Xueyan BaiYuanbo Liu
Dec 14, 2011·Respiratory Medicine·Hyo Jae KangJae-Joon Yim
Feb 29, 2008·Yonsei Medical Journal·Kwang Min KimGyeong-Won Lee
Aug 26, 2018·Hematological Oncology·Mingxiao LangHuilai Zhang
Jan 23, 2013·Nature Reviews. Nephrology·Aditi Sinha, Arvind Bagga
Aug 11, 2020·BMC Cancer·Cong LiHaiyan Yang